Pinnacle Research Group, LLC

Futó vizsgálatok

• Toboroz

  AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  NCT07720271· 3. fázis· Forrás

• Toboroz

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· 3. fázis· Forrás

• Toboroz

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· 3. fázis· Forrás

• Fut, nem toboroz

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· 3. fázis· Forrás

• Toboroz

  A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

  NCT07258849· 1. fázis· Forrás

• Toboroz

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· 3. fázis· Forrás

• Fut, nem toboroz

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  NCT06902519· 1. fázis· Forrás

• Fut, nem toboroz

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

  NCT06643728· 2. fázis· Forrás

• Fut, nem toboroz

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· 2. fázis· Forrás

• Toboroz

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· 3. fázis· Forrás

• Fut, nem toboroz

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· 2/3. fázis· Forrás

• Fut, nem toboroz

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Elhízás3 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Lupus (SLE)1 toboroz
• Magas vérnyomás1 toboroz
• Rheumatoid arthritis1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· 3. fázis· Forrás

• Lezárult

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· 3. fázis· Forrás

• Lezárult

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· 1/2. fázis· Forrás

• Lezárult

  Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

  NCT05616013· 2. fázis· Forrás

• Lezárult

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· 2. fázis· Forrás

• Lezárult

  A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

  NCT05377333· 1. fázis· Forrás

• Toboroz

  ConsideRAte Study - Splenic Stimulation for RA

  NCT05003310· Forrás

• Lezárult

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· 3. fázis· Forrás